Tuesday, November 17, 2026

Blockbuster TOKYO", a training and support program specializing in drug discovery and medical venture businesses, begins accepting entries for the selection program.

Beyond Next Ventures has been commissioned by the Tokyo Metropolitan Government to conduct the "Blockbuster TOKYO" drug discovery and medical venture development support program in fiscal 2020, following fiscal 2018 and 2019. The program will be implemented in FY2020, following FY2018 and FY2019, and participants will be recruited for the selected program. This program consists of two programs: a training program (to be implemented throughout the year) and a selection program (to be implemented from September 2020 to March 2021), and will provide practical support programs for teams with drug discovery and medical seeds (both pre- and post-startup).

In addition to investing in innovative science and technology ventures, Beyond Next Ventures operates one of the largest technology-specific acceleration programs in Japan, providing support to researchers and early-stage technology ventures seeking to commercialize their businesses. One such program is "Blockbuster TOKYO," a development support program for drug discovery and medical ventures, which has been running since fiscal 2018 to accelerate commercialization, create a community, and foster an ecosystem. The program is designed to accelerate commercialization, create a community, and foster an ecosystem.

The features of this program include support for acquiring the knowledge necessary for drug discovery and medical venture businesses, support for management such as hiring human resources, support for business development through matching with investors and business companies, opportunities to use shared laboratories, support for research and development, and support for opportunities to make presentations at various venues including overseas venues. The program provides comprehensive support necessary for drug discovery and medical ventures. Past participants in this program have successfully started their own businesses or raised funds from investors. The program consists of two programs: a training program and a selection program. The training program includes seminars and lectures in January to provide participants with the latest trends in the bio-industry, an overview of entrepreneurship and venture business, practical knowledge about fundraising, and the knowledge necessary for efficient R&D and business alliances in venture companies. Seminars and lectures will be held about once a month. In the selection program, teams with more concrete business plans will receive professional support from mentors with expertise in each field, such as drug discovery (synthesis, non-clinical trials, clinical development, etc.), intellectual property, pharmaceutical affairs, finance, and marketing, as well as practical support in matching the team with the necessary human resources and in research and development, etc. In addition, the MHLW In addition, the mentor team is further enhanced by strengthening cooperation with the Ministry of Health, Labor and Welfare's Medical Venture Total Support Program (MEDISO).
Entry to the training program is open at any time, and entry to the selection program has also begun.

(Please refer to the Blockbuster TOKYO website "Application Guidelines" for detailed conditions.)

The project will support those who fall under either (1) or (2) below. The term "Drug Discovery/Medical Field" refers to the following four fields.

  • Pharmaceuticals/Drug Discovery: small molecule drugs, biopharmaceuticals, vaccines, drug delivery systems, pharmaceutical raw materials, etc.
  • Medical and diagnostic": gene therapy, regenerative medicine (cells, culture media, culture medium, reagents, etc.), immunotherapy, genetic diagnosis, imaging diagnosis, biomarkers, etc.
  • Drug Discovery Support/Contract Services: Contract synthesis and manufacturing, contract analysis, compound library and screening, contract animal production and animal experiment services, CMO (contract manufacturing organization), CRO (contract research organization), SMO (clinical trial organization), drug discovery research support software and laboratory information systems, drug discovery IT, Computational drug discovery, etc.
  • Others": Smart cell industry, bioinformatics, digital technology, etc. that are closely related to the above-mentioned fields, and peripheral technology of the above-mentioned fields that contribute to research and development, etc. in the above-mentioned fields.

(i) Those aiming to commercialize drug discovery/medical venture businesses in Tokyo through startups, etc. (e.g., researchers affiliated with research institutions such as universities and companies, aspiring entrepreneurs, and teams including such persons).

(2) Small and medium-sized enterprises (SMEs) engaged in drug discovery and medical-related businesses that have a place of business in Tokyo or intend to have a place of business in Tokyo in the future (SMEs are defined by the SME Act). (Definition of "SME" is based on the Small and Medium Business Act, as shown in the link below)

note (supplementary information) symbol https://www.chusho.meti.go.jp/faq/faq/faq01_teigi.htm#q1

Schedule (tentative)

  • May 18, 2020 : Entry for the selection program starts
  • June 2020∼March 2021: Implementation of training program (about once a month, applications accepted at any time)
  • June 26, 2020 : Deadline for the first call for applications for the selection program
  • July 17, 2020 : Second application deadline for the selection program
  • September 2020∼March 2021: Implementation of selection program (seminars and study sessions, mentoring, matching, pitch practice sessions, R&D support, use of shared labs, travel to the U.S. events, etc.)

3. area of implementation

This program will be implemented using online tools and in Tokyo (e.g., in the Nihonbashi area of Chuo-ku, Tokyo).

4About Entry (Application) Entry (Application)

Register using the entry form on the Blockbuster TOKYO website.
If you have any questions, please contact the Blockbuster TOKYO Management Office.

Blockbuster TOKYO Websitehttps://www.blockbuster.tokyo

Inquiries Blockbuster TOKYO Management Office: info@blockbuster.tokyo

About Beyond Next Ventures

Beyond Next Ventures, founded in August 2014, is an independent accelerator specializing in incubation investment in technology startups. It is one of the few leading companies in this field in Japan, with abundant investment experience and an excellent track record of operations ranging from support for the commercialization of university seeds to venture investment and growth support, and has been certified as a business promoter under the START Program of the Japan Science and Technology Agency (JST) and a recipient of the NEDO's R&D Venture Support Program. The company manages the largest fund in Japan as an accelerator with a total of nearly 20 billion yen, including the first fund established in February 2015 and the second fund established in October 2018, and invests in numerous technology startups and supports their commercialization and growth. The company invests in a large number of technology startups and supports their commercialization and growth.
In addition to funding, we are also actively involved in commercialization support through the "BRAVE Acceleration Program" (URL: ). http://brave.team/BRAVE is the largest technology-focused acceleration program in Japan for academia. BRAVE is the largest technology-focused acceleration program in Japan, and its practical programs, such as its abundant experience in the JST START program, have led to tangible results.
In February 2019, the shared/wet lab "Beyond BioLAB TOKYO" (URL: ) will be established in Chuo-ku, Tokyo, as a base for providing commercialization support, including R&D, to startup companies in the life science field. http://biolab.beyondnextventures.com/), which provides an environment that promotes entrepreneurship and its rapid growth to technology startups, mainly in the medical and life science fields. From March 2019, the company will launch Co-founders, a co-founder matching platform specializing in technology seeds and researchers at universities and other institutions (URL: https://co-founders.team/) to help build strong start-up teams by providing online matching opportunities and real-life support.

name of companyBeyond Next Ventures, Inc.
EstablishmentAugust 2014
Location1 Nihonbashi Murohon Building 1-4-3 Nihonbashi-Honcho, Chuo-ku, Tokyo
representativeTsuyoshi Ito, President and Representative Director
uniform resouce locatorhttp://beyondnextventures.com


PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。